Bristol-Myers Squibb (BMY) reported a solid second quarter, but analysts at RBC Capital Markets are cautioning that delays in two important drug launches could keep the stock from breaking out of its recent trading range. The investment bank raised its full-year revenue estimate for the company to $50 billion, reflecting the strong quarter, but also flagged that the timing of key product launches has slipped.
Strong quarter, but launch delays
Bristol-Myers, a major pharmaceutical company known for cancer treatments like Opdivo and Eliquis, has been working to diversify its portfolio as some of its top-selling drugs face patent expirations. The company's Q2 results were robust, prompting RBC to lift its revenue outlook. However, the bank's analysts noted that two promising new drugs are taking longer to reach the market than expected.
The first is milvexian, an experimental blood thinner being developed for atrial fibrillation (AFib), a common heart rhythm disorder that increases the risk of stroke. The second is Cobenfy, a treatment for schizophrenia that was approved by the U.S. Food and Drug Administration last year.
RBC said the milvexian delay was largely anticipated by investors, but the Cobenfy delay came as a surprise. The bank noted that the delay removes near-term milestones that often help stocks reprice higher. When a drug's launch is pushed back, it pushes out the potential revenue stream, making it harder for investors to justify a higher valuation.
Execution challenges with Cobenfy
The bigger issue, according to RBC, is execution. The bank flagged that some patients are struggling to reach Cobenfy's effective dose of 125 milligrams because of stomach-related side effects. This can slow early adoption, even if doctors are being encouraged to increase the dose over time.
For a new drug, early uptake is critical. If patients discontinue treatment due to side effects, it can dampen the drug's commercial prospects and make it harder for the company to hit its sales targets. RBC's warning suggests that while the drug has potential, the rollout may be bumpier than initially hoped.
What it means for investors
For everyday investors, the key takeaway is that Bristol-Myers is performing well financially, but its future growth depends heavily on the successful launch of new drugs. The company has been under pressure to replace revenue from older drugs that are losing patent protection, and delays in new launches can weigh on the stock.
RBC's comments suggest that the shares could remain "range-bound" — meaning they may trade within a narrow price band rather than making a decisive move higher. This is often the case when investors are waiting for clarity on a company's growth prospects.
Investors should also note that the stock market reaction to such news can be muted if the delays are already priced in. However, the Cobenfy surprise could add a layer of uncertainty.
Bristol-Myers is not alone in facing these challenges. Many pharmaceutical companies rely on a pipeline of new drugs to sustain growth, and delays are common. The key is to watch how the company manages these setbacks and whether it can accelerate the launches in the coming quarters.
For those holding Bristol-Myers shares, the raised revenue outlook is a positive sign, but the launch delays are a reminder that execution matters as much as the science. As always, it's important to consider your own investment goals and risk tolerance before making any decisions.
In the broader market, pharmaceutical stocks often react to news like this, but the impact can vary. Investors may also want to keep an eye on private credit trends and other market developments that can influence overall sentiment.
RBC's note is a useful reminder that even strong quarterly results can be overshadowed by concerns about the future. For Bristol-Myers, the next few quarters will be crucial in determining whether the company can deliver on its growth promises.
